4wme › Citations

Structures of the Middle East respiratory syndrome coronavirus 3C-like protease reveal insights into substrate specificity.

Needle D, Lountos GT, Waugh DS
Acta Crystallogr D Biol Crystallogr 71 1102-11 (2015)
Related entries: 4wmd, 4wmf

Cited: 54 times
EuropePMC logo PMID: 25945576

Abstract

Middle East respiratory syndrome coronavirus (MERS-CoV) is a highly pathogenic virus that causes severe respiratory illness accompanied by multi-organ dysfunction, resulting in a case fatality rate of approximately 40%. As found in other coronaviruses, the majority of the positive-stranded RNA MERS-CoV genome is translated into two polyproteins, one created by a ribosomal frameshift, that are cleaved at three sites by a papain-like protease and at 11 sites by a 3C-like protease (3 CL(pro)). Since 3 CL(pro) is essential for viral replication, it is a leading candidate for therapeutic intervention. To accelerate the development of 3 CL(pro) inhibitors, three crystal structures of a catalytically inactive variant (C148A) of the MERS-CoV 3 CL(pro) enzyme were determined. The aim was to co-crystallize the inactive enzyme with a peptide substrate. Fortuitously, however, in two of the structures the C-terminus of one protomer is bound in the active site of a neighboring molecule, providing a snapshot of an enzyme-product complex. In the third structure, two of the three protomers in the asymmetric unit form a homodimer similar to that of SARS-CoV 3 CL(pro); however, the third protomer adopts a radically different conformation that is likely to correspond to a crystallographic monomer, indicative of substantial structural plasticity in the enzyme. The results presented here provide a foundation for the structure-based design of small-molecule inhibitors of the MERS-CoV 3 CL(pro) enzyme.

Reviews - 4wme mentioned but not cited (1)

  1. Repositioning microbial biotechnology against COVID-19: the case of microbial production of flavonoids. Goris T, Pérez-Valero Á, Martínez I, Yi D, Fernández-Calleja L, San León D, Bornscheuer UT, Magadán-Corpas P, Lombó F, Nogales J. Microb Biotechnol 14 94-110 (2021)

Articles - 4wme mentioned but not cited (8)

  1. Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor. Kim Y, Liu H, Galasiti Kankanamalage AC, Weerasekara S, Hua DH, Groutas WC, Chang KO, Pedersen NC. PLoS Pathog 12 e1005531 (2016)
  2. Structures of the Middle East respiratory syndrome coronavirus 3C-like protease reveal insights into substrate specificity. Needle D, Lountos GT, Waugh DS. Acta Crystallogr D Biol Crystallogr 71 1102-1111 (2015)
  3. Critical Assessment of the Important Residues Involved in the Dimerization and Catalysis of MERS Coronavirus Main Protease. Ho BL, Cheng SC, Shi L, Wang TY, Ho KI, Chou CY. PLoS One 10 e0144865 (2015)
  4. COVID-19: Rational discovery of the therapeutic potential of Melatonin as a SARS-CoV-2 main Protease Inhibitor. Feitosa EL, Júnior FTDSS, Nery Neto JAO, Matos LFL, Moura MHS, Rosales TO, De Freitas GBL. Int J Med Sci 17 2133-2146 (2020)
  5. Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses. Nathan A, Rossin EJ, Kaseke C, Park RJ, Khatri A, Koundakjian D, Urbach JM, Singh NK, Bashirova A, Tano-Menka R, Senjobe F, Waring MT, Piechocka-Trocha A, Garcia-Beltran WF, Iafrate AJ, Naranbhai V, Carrington M, Walker BD, Gaiha GD. Cell 184 4401-4413.e10 (2021)
  6. Identification of mutation resistance coldspots for targeting the SARS-CoV2 main protease. Krishnamoorthy N, Fakhro K. IUBMB Life 73 670-675 (2021)
  7. Structural basis for catalysis and substrate specificity of a 3C-like cysteine protease from a mosquito mesonivirus. Kanitz M, Blanck S, Heine A, Gulyaeva AA, Gorbalenya AE, Ziebuhr J, Diederich WE. Virology 533 21-33 (2019)
  8. Structural similarities between SARS-CoV2 3CLpro and other viral proteases suggest potential lead molecules for developing broad spectrum antivirals. Bafna K, Cioffi CL, Krug RM, Montelione GT. Front Chem 10 948553 (2022)


Reviews citing this publication (12)

  1. Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic. Gasmi A, Noor S, Tippairote T, Dadar M, Menzel A, Bjørklund G. Clin Immunol 215 108409 (2020)
  2. Middle East respiratory syndrome coronavirus: transmission, virology and therapeutic targeting to aid in outbreak control. Durai P, Batool M, Shah M, Choi S. Exp Mol Med 47 e181 (2015)
  3. Drug Discovery Strategies for SARS-CoV-2. Shyr ZA, Gorshkov K, Chen CZ, Zheng W. J Pharmacol Exp Ther 375 127-138 (2020)
  4. A Comprehensive Review about the Molecular Structure of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Insights into Natural Products against COVID-19. Saied EM, El-Maradny YA, Osman AA, Darwish AMG, Abo Nahas HH, Niedbała G, Piekutowska M, Abdel-Rahman MA, Balbool BA, Abdel-Azeem AM. Pharmaceutics 13 1759 (2021)
  5. Development of Small-Molecule MERS-CoV Inhibitors. Liang R, Wang L, Zhang N, Deng X, Su M, Su Y, Hu L, He C, Ying T, Jiang S, Yu F. Viruses 10 E721 (2018)
  6. The SARS-CoV-2 main protease (Mpro): Structure, function, and emerging therapies for COVID-19. Hu Q, Xiong Y, Zhu GH, Zhang YN, Zhang YW, Huang P, Ge GB. MedComm (2020) 3 e151 (2022)
  7. MERS-CoV: epidemiology, molecular dynamics, therapeutics, and future challenges. Rabaan AA, Al-Ahmed SH, Sah R, Alqumber MA, Haque S, Patel SK, Pathak M, Tiwari R, Yatoo MI, Haq AU, Bilal M, Dhama K, Rodriguez-Morales AJ. Ann Clin Microbiol Antimicrob 20 8 (2021)
  8. New perspectives on natural flavonoids on COVID-19-induced lung injuries. Santana FPR, Thevenard F, Gomes KS, Taguchi L, Câmara NOS, Stilhano RS, Ureshino RP, Prado CM, Lago JHG. Phytother Res 35 4988-5006 (2021)
  9. An Overview of Current Knowledge of Deadly CoVs and Their Interface with Innate Immunity. Zhang Y, Gargan S, Lu Y, Stevenson NJ. Viruses 13 560 (2021)
  10. Druggable targets from coronaviruses for designing new antiviral drugs. Silva LR, da Silva Santos-Júnior PF, de Andrade Brandão J, Anderson L, Bassi ÊJ, Xavier de Araújo-Júnior J, Cardoso SH, da Silva-Júnior EF. Bioorg Med Chem 28 115745 (2020)
  11. An Evaluation of the Potential of Essential Oils against SARS-CoV-2 from In Silico Studies through the Systematic Review Using a Chemometric Approach. Torres Neto L, Monteiro MLG, Galvan D, Conte-Junior CA. Pharmaceuticals (Basel) 14 1138 (2021)
  12. Insights into SARS-CoV-2: Medicinal Chemistry Approaches to Combat Its Structural and Functional Biology. Zhuo LS, Wang MS, Yang JF, Xu HC, Huang W, Shang LQ, Yang GF. Top Curr Chem (Cham) 379 23 (2021)

Articles citing this publication (33)

  1. Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants. Tahir Ul Qamar M, Alqahtani SM, Alamri MA, Chen LL. J Pharm Anal 10 313-319 (2020)
  2. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice. Rathnayake AD, Zheng J, Kim Y, Perera KD, Mackin S, Meyerholz DK, Kashipathy MM, Battaile KP, Lovell S, Perlman S, Groutas WC, Chang KO. Sci Transl Med 12 eabc5332 (2020)
  3. Characteristics of flavonoids as potent MERS-CoV 3C-like protease inhibitors. Jo S, Kim H, Kim S, Shin DH, Kim MS. Chem Biol Drug Des 94 2023-2030 (2019)
  4. Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents. Mody V, Ho J, Wills S, Mawri A, Lawson L, Ebert MCCJC, Fortin GM, Rayalam S, Taval S. Commun Biol 4 93 (2021)
  5. Structural and Evolutionary Analysis Indicate That the SARS-CoV-2 Mpro Is a Challenging Target for Small-Molecule Inhibitor Design. Bzówka M, Mitusińska K, Raczyńska A, Samol A, Tuszyński JA, Góra A. Int J Mol Sci 21 E3099 (2020)
  6. Letter In silico and in vitro evaluation of kaempferol as a potential inhibitor of the SARS-CoV-2 main protease (3CLpro). Khan A, Heng W, Wang Y, Qiu J, Wei X, Peng S, Saleem S, Khan M, Ali SS, Wei DQ. Phytother Res 35 2841-2845 (2021)
  7. Comprehensive Insights into the Catalytic Mechanism of Middle East Respiratory Syndrome 3C-Like Protease and Severe Acute Respiratory Syndrome 3C-Like Protease. Wang H, He S, Deng W, Zhang Y, Li G, Sun J, Zhao W, Guo Y, Yin Z, Li D, Shang L. ACS Catal 10 5871-5890 (2020)
  8. Proton-Coupled Conformational Activation of SARS Coronavirus Main Proteases and Opportunity for Designing Small-Molecule Broad-Spectrum Targeted Covalent Inhibitors. Verma N, Henderson JA, Shen J. J Am Chem Soc 142 21883-21890 (2020)
  9. Macro Domain from Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Is an Efficient ADP-ribose Binding Module: CRYSTAL STRUCTURE AND BIOCHEMICAL STUDIES. Cho CC, Lin MH, Chuang CY, Hsu CH. J Biol Chem 291 4894-4902 (2016)
  10. Prediction and biochemical analysis of putative cleavage sites of the 3C-like protease of Middle East respiratory syndrome coronavirus. Wu A, Wang Y, Zeng C, Huang X, Xu S, Su C, Wang M, Chen Y, Guo D. Virus Res 208 56-65 (2015)
  11. Identification of potential inhibitors of SARS-CoV-2 main protease from Aloe vera compounds: A molecular docking study. Mpiana PT, Ngbolua KT, Tshibangu DST, Kilembe JT, Gbolo BZ, Mwanangombo DT, Inkoto CL, Lengbiye EM, Mbadiko CM, Matondo A, Bongo GN, Tshilanda DD. Chem Phys Lett 754 137751 (2020)
  12. Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors. Chiou WC, Hsu MS, Chen YT, Yang JM, Tsay YG, Huang HC, Huang C. J Enzyme Inhib Med Chem 36 147-153 (2021)
  13. Structure-based virtual screening of phytochemicals and repurposing of FDA approved antiviral drugs unravels lead molecules as potential inhibitors of coronavirus 3C-like protease enzyme. Bahadur Gurung A, Ajmal Ali M, Lee J, Abul Farah M, Mashay Al-Anazi K. J King Saud Univ Sci 32 2845-2853 (2020)
  14. Computational selection of flavonoid compounds as inhibitors against SARS-CoV-2 main protease, RNA-dependent RNA polymerase and spike proteins: A molecular docking study. Rameshkumar MR, Indu P, Arunagirinathan N, Venkatadri B, El-Serehy HA, Ahmad A. Saudi J Biol Sci 28 448-458 (2021)
  15. Manipulated bio antimicrobial peptides from probiotic bacteria as proposed drugs for COVID-19 disease. Balmeh N, Mahmoudi S, Fard NA. Inform Med Unlocked 23 100515 (2021)
  16. A Potential Peptide From Soy Cheese Produced Using Lactobacillus delbrueckii WS4 for Effective Inhibition of SARS-CoV-2 Main Protease and S1 Glycoprotein. Chourasia R, Padhi S, Chiring Phukon L, Abedin MM, Singh SP, Rai AK. Front Mol Biosci 7 601753 (2020)
  17. Structure-based virtual screening and molecular dynamics of phytochemicals derived from Saudi medicinal plants to identify potential COVID-19 therapeutics. Alamri MA, Altharawi A, Alabbas AB, Alossaimi MA, Alqahtani SM. Arab J Chem 13 7224-7234 (2020)
  18. In Silico Mutagenesis-Based Remodelling of SARS-CoV-1 Peptide (ATLQAIAS) to Inhibit SARS-CoV-2: Structural-Dynamics and Free Energy Calculations. Khan A, Umbreen S, Hameed A, Fatima R, Zahoor U, Babar Z, Waseem M, Hussain Z, Rizwan M, Zaman N, Ali S, Suleman M, Shah A, Ali L, Ali SS, Wei DQ. Interdiscip Sci 13 521-534 (2021)
  19. An in-silico evaluation of COVID-19 main protease with clinically approved drugs. Tachoua W, Kabrine M, Mushtaq M, Ul-Haq Z. J Mol Graph Model 101 107758 (2020)
  20. The Novel Drug Discovery to Combat COVID-19 by Repressing Important Virus Proteins Involved in Pathogenesis Using Medicinal Herbal Compounds. Mahmoudi S, Balmeh N, Mohammadi N, Sadeghian-Rizi T. Avicenna J Med Biotechnol 13 107-115 (2021)
  21. A dual protease approach for expression and affinity purification of recombinant proteins. Raran-Kurussi S, Waugh DS. Anal Biochem 504 30-37 (2016)
  22. Development of Effective Therapeutic Molecule from Natural Sources against Coronavirus Protease. Fadaka AO, Sibuyi NRS, Martin DR, Klein A, Madiehe A, Meyer M. Int J Mol Sci 22 9431 (2021)
  23. Dimethyl sulfoxide reduces the stability but enhances catalytic activity of the main SARS-CoV-2 protease 3CLpro. Ferreira JC, Fadl S, Ilter M, Pekel H, Rezgui R, Sensoy O, Rabeh WM. FASEB J 35 e21774 (2021)
  24. SARS-CoV-2 3CLpro whole human proteome cleavage prediction and enrichment/depletion analysis. Prescott L. Comput Biol Chem 98 107671 (2022)
  25. The effects of add-on therapy of Phyllanthus Emblica (Amla) on laboratory confirmed COVID-19 Cases: A randomized, double-blind, controlled trial. Varnasseri M, Siahpoosh A, Hoseinynejad K, Amini F, Karamian M, Yad MJY, Cheraghian B, Khosravi AD. Complement Ther Med 65 102808 (2022)
  26. Rational Discovery of Antiviral Whey Protein-Derived Small Peptides Targeting the SARS-CoV-2 Main Protease. Gambacorta N, Caputo L, Quintieri L, Monaci L, Ciriaco F, Nicolotti O. Biomedicines 10 1067 (2022)
  27. Activity-Based Protein Profiling Identifies ATG4B as a Key Host Factor for Enterovirus 71 Proliferation. Sun Y, Zheng Q, Wang Y, Pang Z, Liu J, Yin Z, Lou Z. J Virol 93 e01092-19 (2019)
  28. Human Superantibodies to 3CLpro Inhibit Replication of SARS-CoV-2 across Variants. Glab-Ampai K, Kaewchim K, Saenlom T, Thepsawat W, Mahasongkram K, Sookrung N, Chaicumpa W, Chulanetra M. Int J Mol Sci 23 6587 (2022)
  29. Protocetraric and Salazinic Acids as Potential Inhibitors of SARS-CoV-2 3CL Protease: Biochemical, Cytotoxic, and Computational Characterization of Depsidones as Slow-Binding Inactivators. Fagnani L, Nazzicone L, Bellio P, Franceschini N, Tondi D, Verri A, Petricca S, Iorio R, Amicosante G, Perilli M, Celenza G. Pharmaceuticals (Basel) 15 714 (2022)
  30. Thiazole-based SARS-CoV-2 protease (COV Mpro ) inhibitors: Design, synthesis, enzyme inhibition, and molecular modeling simulations. Elsayed RW, Sabry MA, El-Subbagh HI, Bayoumi SM, El-Sayed SM. Arch Pharm (Weinheim) 355 e2200121 (2022)
  31. Bioinformatics and network pharmacology-based study to elucidate the multi-target pharmacological mechanism of the indigenous plants of Medina valley in treating HCV-related hepatocellular carcinoma. Alamri MA. Saudi Pharm J 31 1125-1138 (2023)
  32. Finding potential inhibitors for Main protease (Mpro) of SARS-CoV-2 through virtual screening and MD simulation studies. Ahamed NA, Arif IA. Saudi J Biol Sci 30 103845 (2023)
  33. In Silico Screening of Natural Flavonoids against 3-Chymotrypsin-like Protease of SARS-CoV-2 Using Machine Learning and Molecular Modeling. Cai L, Han F, Ji B, He X, Wang L, Niu T, Zhai J, Wang J. Molecules 28 8034 (2023)


Quick links